Phase III SunRISe-2 Trial Compares Gem-iDRS and Cetrelimab to Chemoradiation for MIBC Bladder Preservation - Andrea Necchi
Andrea Necchi
Andrea Necchi presents SunRISe-2, a Phase III trial randomizing 518 muscle-invasive bladder cancer patients refusing or unfit for cystectomy to Gem-iDRS plus cetrelimab versus chemoradiation.